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Biological surface properties in 
extracellular vesicles and their 
effect on cargo proteins
Laura Santucci1, Maurizio Bruschi1, Genny Del Zotto  2, francesca Antonini2, 
Gian Marco Ghiggeri1,3, isabella panfoli4 & Giovanni candiano1
Ultracentrifugationon sucrose density gradientappears to be the best purification protocol for 
extracellular vesicle (EVs) purification. After this step, to reduce disulfide bridges linking exogenous 
proteins to the vesicles, the collected samples are routinely washed and treated with dithiothreitol 
(DTT). Such incubations are performed at temperatures ranging from room temperature up to 95 °C, 
with either Tris or PBS as buffers. We re-investigated these steps on both exosomes and microvesicles 
purified from blood (serum) and urine by electrophoretic separation, silver staining and western blots 
analysis. Data confirm that an extra centrifugation on a sucrose cushion can effectively eliminate 
contaminants. Tris buffer (50 Mm) and β-mercaptoethanol as a reducing agent at room temperature 
dramatically improved either sample cleaning. By contrast, especially for exosomes PBS buffer and 
DTT, above 37 °C, caused massive protein aggregations, yielding blurred SDS-PAGE gels in both 
samples. Immuno-blot analyses demonstrated that in PBS-DTT contamination with albumin (in serum) 
or with uromodulin (in urine) occurs. DTT, likely due to its two–SH groups, might form scrambled 
SS-bonds promoting EVs interaction with environmental macromolecules via disulphide bridges. 
Therefore, to obtain maximum vesicle purity for biomarker investigations and to maximize both 
presence of EVs proteins and their accessibility, use of DTT is not recommended.
Extracellular membrane vesicles (EVs) from biological fluids have been proposed as a promising source of protein 
biomarkers1. Microvesicles (MVs, 100–1,000 nm)2 and exosomes (EXOs, 30–100 nm)3 are shed by all mammalian 
cells, including malignant ones. EVs can transfer proteins, various RNA forms, and other cellular components 
contributing to intercellular communication network4. Currently considered as a potential reservoir of protein 
markers, EVs have the advantage to circumvent the challenge represented by sera, where the dynamic protein 
concentration range can span up to 10–12 orders of magnitude. The active role of exosomes in cancer biology 
has been established. Cancer cells secrete EVs implied in cancer growth and metastasis that have a potential for 
biomarker identification5. We have previously shown that most of urinary proteome contained in the EXOs can 
be effectively utilized to study the whole urinary tract6. Also, urinary EXOs possess oncogenic properties7. In a 
recent report, investigations on urinary EXOs resulted in the detection of few antigens that, with high specificity 
and sensitivity, directly correlated with alterations in prostate cancer tissues, allowed a better patient stratifica-
tion8. We have also shown that both MV sand EXOs conduct aerobic metabolism9. Such metabolic ability of EVs 
bears a clinical relevance, especially for MVs that seem to more closely reflect the cell of origin, as they originate 
from the plasma membrane. This opens the perspective to utilize MVs as sensors of the metabolic state of the 
organism, especially in the case of the premature newborns10.
Although the analysis of EVs, especially those derived from blood, appears highly promising in for an 
early-stage diagnosis the field of precision medicine, from a technological point of view the purification method 
is quite laborious and presents potential pitfalls. In fact, especially when EVs are separated from biological flu-
ids, the presence of other dimensionally similar “bodies”11 can represent an obstacle to their utilization. Several 
purification methods have been reported. Some of them take advantage of precipitation with salts (such as ammo-
nium sulphate), polyethylene glycol (PEG) or organic solvents12. Others suggest purification via filtration using 
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different types of membranes, bind-elute size exclusion chromatography or even capture with specific antibod-
ies3,13–19. Many of these methods are currently under discussion: while ultracentrifugation is the most aknowl-
edged20 method, the best seem to be those utilizing a sucrose density gradient, or a density cushion of known 
sucrose concentration that can significantly reduce the contaminant as abundant proteinacious presence and 
lipoprotein21–26 particles.
The generally accepted protocol for MVs/EXOs purification also includes a washing step followed by an incuba-
tion with dithiothreitol (DTT), to reduce possible SS-bonds to minimize the binding of non-vesicular proteins to 
the EVs. Such incubations with DTT are generally performed at temperatures ranging from 37 °C up to 95 °C27–30. 
The use of different buffers is also recommended, the preferred ones being Tris5,9,28,31,32 or phosphate buffered 
saline (PBS)33–35. Even though several papers described different purification methods for EVs, only few of them 
attempted to assess the quality and pureness of the sample by performing an electrophoretic analysis conducing 
an in-depth study into the gel band patterns.
Here, after are-evaluation by electrophoretic analysis of the above-mentioned methods, we present novel data 
supporting the notion that to obtain both EXOs and MVs free of major non-vesicular contaminants, coming from 
bodily fluid abundant proteins such as albumin and uromodulin a particular strategy is needed23,36–39.
Results
Sampling and analyses. MV and EXO were isolated by centrifugation from either blood or urine (second 
morning urine) from twelve healthy fasting donors (6 males and 6 females). Each sample was divided in aliquots 
and the different analyses were performed (cytofluorimetric validation, dynamic light scattering analysis, gel 
electrophoresis staining and western blotting) according to the method detailed in Supplementary Figs S1 and S2.
Sample loading was optimized by loading the same volume (1 ml for both serum and plasma) for all samples 
regardless of the sample protein concentrations. For western blot, samples were aligned with β-actin. The protein 
content of each pellet after purification was also tested (see Methods).
To choose the best anticoagulant for blood collection, several tests were performed. Figure 1a shows the elec-
trophoretic separation of three different sera (lanes 2, 5, 8), compared to plasma samples treated with two dif-
ferent anticoagulants, namely: EDTA (lanes 1, 4, 7) and sodium citrate (lanes 3, 6, 9). The cleanest pattern was 
obtained using EDTA. This result is even more evident in EXOs (Panel b). On the contrary, plasma treated with 
Sodium citrate tends to generate smearyruns (see bands in Fig. 1, in particular those highlighted with an asterisk), 
probably due to calcium bridges. A serum (lane 10) and a plasma (lane 11) pools were also run to confirm the 
results.
Flow cytometry. As shown in Fig. 2 (left), MVs obtained from both serum and plasma were identified based 
on their dimensions and, to avoid debris, to their negativity to Phalloidin, a cyclic peptide that binds to f-actin 
with high affinity40. Then, to verify if they were compatible with platelet-derived MVs, samples were labeled with 
anti-CD41a.
The smaller micro-particles, gated on the basis of their physical dimensions, were identified as EXOs due to 
their expression of CD81 and CD63 (Fig. 2, right). When comparing MVs and EXOs physical parameters (for-
ward scatter FSC vs. side scatter SSC) of serum and plasma, it is clear that serum samples have less smear and 
seem to be cleaner. Moreover, when analyzing MVs coming from the same donor for the expression of CD41a, in 
serum it is possible to discriminate two different population (CD41a+ and CD41a−) while information was less 
clear in plasma. These analyses support the idea that serum could be the best blood-derived fluid to understand 
the as yet unclear surface interaction phenomena characteristic of MVs or EXOs.
Figure 1. Representative electrophoresis of microvesicles (a) and exosomes (b) obtained from 1 ml of three 
different EDTA plasma (1, 4, 7), sera (2, 5, 8), sodium citrate plasma (3, 6, 9), serum pool (10) and EDTA 
plasma pool (11) of healthy donors. SDS-PAGE were performed onto 8–16% T gels. Both gels were visualized by 
silver staining.
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Dynamic light scattering analysis. Dynamic light scattering analysis was used to determine the size and 
purity of particles versus intensity (optical density). Results reveal a Gaussian distribution profile with a mean 
peak at 500 ± 65 nm or 50 ± 5 nm, the typical size for MVs or EXOs (Fig. 3), respectively. Panel a show the peaks 
of MVs and panel b of EXOs obtained from 1 ml of serum/plasma and 12 ml of urine, after sucrose cushion 
centrifugation. Samples visualized in the first lane are without reducing agent, while those in the second and 
third lanes were treated by DTT and β-mercaptoethanol (β-ME), respectively. Statistical difference between the 
sizes of MVs or EXOs (P < 0.05 for both types of extracellular vesicles) isolated using the different protocols was 
determined. Also, this analysis shows that the cleanest peaks were obtained for serum with respect to plasma that 
displays additional peaks. Also, the most suitable protocol for the three biological fluids was the one utilizing 
β-ME as a reducing agent, yielding narrower peaks throughout. Data confirm that serum is the cleanest sample, 
respect to plasma.
Isolation and SDS-PAGE of serum extracellular vesicles. Considering the above-mentioned results, 
we decided to use exclusively serum, as blood-derived biological fluid. Samples were centrifuged twice, first to 
eliminate cell debris and subsequently to remove the microscopic particle sediments. Then, MVs and EXOs frac-
tions (22,000 and 100,000 × g respectively) were purified. The same flow-chart (Supplementary Fig. S1) procedure 
was used for the analysis of the serum and urinary EVs. Then, electrophoresis of MVs proteins was performed on 
1 mL of three different healthy donor sera (Fig. 4, N1–N3). Panel a shows a representative silver staining of serum 
proteins purified by centrifugation in the absence of a sucrose density cushion. Panels b,c show profiles of the 
same samples after an extra purification step by centrifugation on a sucrose cushion (Supplementary Fig. S2). This 
supplementary step was designed to eliminate contaminants in pellet preparation, such as non-specific proteins 
and large protein aggregates, which sediment by centrifugation but do not float on a sucrose cushion. In Panel 
b incubation was do neat room temperature while in Panel c at 37°Cfor 30 minutes. In both cases Tris was the 
buffer. The best result was obtained in the un heated sample after the application of sucrose cushions.
Figure 2. Cytofluorimetric analysis of microvesicles and exosomes obtained from plasma and serum of healthy 
donors. PB was collected in EDTA tubes. Top dot plot shows SSC beads analyzed by their physical parameters, 
namely side scatter (SSC) and forward scatter (FSC). Beads allowed to set gates used to define vesicles 
dimensions. Among events of microvesicular dimension only those negative for Phalloidin were considered 
MV and further analyzed for CD41a expression (left side dot plots). Considering the small dimensions of 
exosomes, to analyze their CD63 and CD81 expression (right side dot plots) a fluorescence minus one analysis 
was performed. CD41a, CD63 and CD81 histograms show both negative (light grey) and positive (dark grey) 
samples. The experiment is representative of other three.
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Once we chose this condition, further procedure modifications (Fig. 5) were conducted on two different sera 
(N1–N2). Two different buffers, Tris (Panels a,b) or PBS (Panels c,d) were evaluated together with two different 
reducing agents, namely DTT (Panels a,c) or β-ME (Panels b,d). Results allowed to establish that the best sample 
cleaning was obtained using Tris as buffer with β-ME on the sucrose cushion.
Identical experiments were performed also on EXOs (Fig. 6) purified by ultracentrifugation without (lane 
a) or with a sucrose cushions (lanes b–h), using Tris (lanes b–e) or PBS (lanes f–h) as buffer. DTT was added 
to samples in lanes c and f, whereas β-ME in those in lanes d and g. No reducing agent was added to serum 
sample in lane b. Notably, DTT, in the presence of either Tris or PBS, causes a massive aggregation of proteins, 
Figure 3. Representative dynamic light scattering analysis of microvesicles (a) and exosomes (b) obtained from 
1 ml of serum/plasma and 12 ml of urine, after sucrose cushion. The graph reports the size (nm) of the particles 
(x-axis) versus intensity (Optical Density y-axis). The samples visualized in the first row are without reducing 
agents while those in the second and third row were treated with by DTT and β-ME, respectively.
Figure 4. Representative electrophoresis of microvesicles obtained from 1 ml of three different sera (N1–
N3) of healthy donors. Gels are cropped to better highlight the different methods used. Silver staining of 
samples without (a) or with (b,c) application of sucrose cushions. In panel b incubation was conducted at 
room temperature, while in (c) incubation was at 37 °C; in both cases the buffer used is Tris. SDS-PAGE was 
performed onto 8–16% T gels.
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Figure 5. Representative electrophoresis of micro-vesicles obtained from 1 ml of two different sera (N1–N2) of 
healthy donors. Gels are cropped to better highlight the different methods used. Silver staining representative of 
samples isolated by sucrose cushion centrifugations utilizing as buffer Tris (a,b) or PBS (c,d). In panels a and c 
samples were added of DTT while those in panel b and d were added of β-ME. SDS-PAGE was performed onto 
8–16% T gel.
Figure 6. Representative silver staining of exosomes obtained from 1 ml of serum from healthy donors. Gels are 
cropped to better highlight the different methods used. Electrophoresis of samples isolated without (a) or with 
the use of sucrose cushions (b–h) utilizing as buffer Tris (b–e) or PBS (f–h). Samples visualized in lanes (c,f) 
were treated with the addition of DTT, those in (d,g) were added of β-ME, while those in (e,h) were added of 
TBP. Serum in (b) is without reducing agent. SDS-PAGE was performed onto 8–16% T gels.
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likely due to its double –SH residues, which are absent using β-ME. Furthermore, the use of PBS in the presence 
of DTT worsened the run in EXOs when compared to MVs, the possible cause being the formation of ionic 
bridges between EXOs surface proteins and other extra-vesicular proteins, due to the reducing environment. A 
third agent, Tri-buthyl-Phosphine (TBP) which is a very strong reducing agent was also utilized in serum EXOs 
purification (see lanes e,h). Interestingly, also TBP which does not contain –SH groups can create artifacts (see 
lanes e,h), likely promoting direct S-S bonding among SH-containing proteins, similarly to effect of DTT. The 
mechanism may be the initial strong reduction of the EXOs SH-containing proteins in the TBP-containing envi-
ronment, over sucrose density cushions. Then, as soon as during ultracentrifugation the EXOs cross the cushions, 
a rapid random re-oxidation of -SH groups would occur.
Supplementary Fig. S3 shows the representative results of Tris buffer concentration titration (50 mM in panel 
a, 250 mM in panel b and 500 mM in panels c,d) on EXOs obtained from three different sera (N1–N3). 50 mM 
Tris appears the best buffer concentration, likely due toa “salting out” effect of high molar concentrations of Tris. 
Also for EXOs in the same conditions, the addition of β-ME (Panel c) produced the cleanest runs confirming the 
results obtained for MVs.
Isolation and SDS-PAGE of urinary extracellular vesicles. The second biological fluid tested was 
urine. Figure 7 shows a representative silver staining of MVs proteins from 12 mL of urine of healthy donors, 
isolated without (lane a) or with a sucrose density cushion (lanes b–f) in the presence of either Tris (lanes b–d) 
or PBS (lanes e,f). Samples in lanes c and e were treated with DTT where as those in lanes d and f with β-ME. In 
lane b no reducing agent was added. These results confirm those obtained for serum, although in the case of urine 
the differences between the two buffers were less evident. The major protein that strongly decreases in presence of 
Tris and β-ME (lane d) is uromodulin, normally abundant in urines and particularly rich in cystein (visible as a 
negatively stained band in the upper gel region, at >100 KDa). Figure 8 shows the result of the protein separation 
of EXOs obtained from urine without (lane a) or with the use of a sucrose density cushion (lanes b–f) utilizing 
either Tris (lanes b–d) or PBS (lanes e–f), and with DTT (lanes c,e) or β-ME (lanes d,f). In b there was no reduc-
ing agent. Again, addition of β-ME improved the separation in PBS, whereas DTT worsened the patterns in the 
presence of either buffer.
Western blot analysis of serum and urinary extracellular vesicles. The above results were con-
firmed by the experiments described in Fig. 9, showing results representative western blot of MVs and EXOs from 
serum and urine samples. As already mentioned, western blots were normalised by alignment of sample bands 
to β-actin. In this way it was possible to eliminate any artifact due to aggregated proteins. Then, polyclonal rabbit 
anti-human albumin (HSA) and polyclonal sheep anti-human uromodulin were used in samples treated without 
(lane a) or with sucrose density cushion (lanes b–f) by Tris (lanes b–d) or PBS (lanes e–f). Samples in c and e were 
treated with DTT whereas those in d and f with β-ME. In lane b, both for serum and urine, no reducing agent 
was added. Consistently to what already observed, the best conditions are obtained in presence of Tris-buffer 
Figure 7. Representative silver staining of microvesicles obtained from 12 ml of urine of healthy donors. 
Gels are cropped to better highlight the different methods used. Electrophoresis without (a) and on a sucrose 
cushions (b–h) utilizing as buffer Tris (b–e) or PBS (f–h). The sample visualized in lanes (c,f) were added of 
DTT, those in (d,g) of β-ME while those in (e,h) of TBP. Serum in (b) is without reducing agent. SDS-PAGE was 
performed onto 8–16% T gels.
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Figure 8. Representative silver staining of exosomes obtained from 12 ml of urine of normal volunteers. 
Gels are cropped to better highlight the different methods used. Electrophoresis without (a) and on a sucrose 
cushions (b–f) utilizing as buffer Tris (b–d) or PBS (e–f). The sample visualized in lane (c,e) is treated with the 
addition of reducent DTT while in panel d and f of β-ME. In the serum (b) there is no reducing agent. SDS-
PAGE was performed onto 8–16% T gels.
Figure 9. Western blot of MVs/EXOs of serum/urine from healthy donors with anti-human monoclonal mouse 
β-Actin, polyclonal rabbit serum anti-albumin (HSA) or sheep anti-uromodulin from samples isolated without 
(a) or with sucrose cushions (b–f) utilizing as buffer Tris (b–d) or PBS (e,f). Samples in (c,e) were added of 
DTT while those in (d,f) of β-ME. In the serum/urine (b) there is no reducing agent. Gels are cropped to better 
highlight the results. SDS-PAGE was performed onto 8–16% T gels.
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plus β-ME, as confirmed in lane d by the markedly reduced levels of albumin and uromodulin as compared, for 
example, to lane e, where DTT was the reducing agent.
To further confirm the removal of non-vesicular contaminant proteins, we analyzed the serum supernatants 
from the washing steps after sucrose gradient. Supplementary Fig. 4 shows the supernatants from the first (MVs, 
lanes 1, 3, 5; EXOs, lanes 7, 9, 11) and the last (MVs, lanes 2, 4, 6; EXOs, lanes 8, 10, 12) wash. Polyclonal rabbit 
anti-human albumin (HSA) (chosen as a representative being among the most abundant proteins in the electro-
phoretic pattern) was used. In EXOs washings, albumin is more abundant, as expected since these vesicles yielded 
cleanest pellets after sucrose density gradient. Such result was less evident in the MV. In the respective pellets we 
studied the presence of apolipoprotein A1 (Apo-A1). This protein is a major component of HDL co-sediment 
with EXOs41. On the same gel, after membrane stripping, we also detected apolipoprotein E (Apo-E) and C 
(Apo-C). Supplementary Fig. 5 is a representative western blot with anti-human Apo-A1, Apo-E or Apo-C of 
EXOs pellets isolated after sucrose density gradient treated without (lanes 1, 4, 7), or with reducing agents (DTT, 
lanes 2, 5, 8 or β-ME, lanes 3, 6, 9). Anti β-actin was used as loading control. Data show that the sample treated 
with β-ME is the cleanest, with respect to the presence of HDL, consistently with previous results. By contrast, the 
absence of both ApoE and ApoC, rule out the presence of chylomicrons and VLDL, respectively.
Discussion
EVs are constitutively released by cells into the extracellular environment42 and are present in all body fluids. 
EVs have gained widespread interest due to their ability to carry bioactive components such as RNAs, DNA, and 
proteins. However, besides their luminal cargo, EVs can also carry a significant surface cargo encompassing DNA 
and especially proteins likely acquired in body fluids after shedding43. Being especially true in the case of blood, 
this renders technically challenging the investigation of the EVs. Little is known about the purification conditions 
that favour the external adsorption of extravesicular proteins onto EVs or their loss. Moreover, most studies have 
considered EVs as a whole and did not distinguish EXOs from MVs. By contrast, our investigation focused on 
EXOs and MVs singularly. In particular, the present study involved an electrophoretic approach to study the 
inherent heterogeneity of the surface cargo of EXOs and MVs, depending on the purification conditions and the 
kind of EVs.
Although a combination of ultracentrifugation and size-exclusion chromatography (SEC) is often used, the 
gold-standard procedure for EVs purification is ultracentrifugation on a sucrose density gradient (or on a sucrose 
cushion), followed by washing steps and a final treatment with DTT, meant to reduce possible SS-bonds among 
EVs13,21,30. However, the content of surface thiols can also influence the interaction of EVs with environmen-
tal proteins especially those bearing reactive thiol moieties43. Our investigation showed that DTT treatment is 
far from being optimal, at any temperature since DTT appears to induce the formation of scrambled SS-bonds 
linking non-vesicular proteins to the surface of EVs, in particular, albumin in sera and uromodulinin urine, as 
demonstrated by immuno-blotting. Both these proteins display a high content of Cys residues (35 in albumin44, 
48 in uromodulin and fibrinogen 58 cyst45 which could promote the formation of disulphide bridges43.
Data clearly show that EVs contamination could be reduced using Tris as buffer and β-ME as a reducing agent, 
all steps better performed at Tamb. These conditions are thus recommended in order to obtain maximum purity 
vesicles for biomarker investigations. As far as MVs are concerned, the presence of Tris lowered contamination 
also at 37 °C (Fig. 4). However, when Tris concentration was increased, regardless of the presence of β-ME, a 
“salting-out” effect (Fig. S3) causing a massive protein aggregation in exosomes was observed. Nanoparticle anal-
ysis confirmed that the cleanest samples, as judged by electrophoresis, are those obtained in the presence of β-ME 
(where single peaks are seen) after sucrose density gradient. In the absence of reducing agent or in the presence 
of DTT other smaller peaks are present, coming from material with different size. This is more evident in the 
case of MVs. Nanoparticle analysis also showed that the above-mentioned conditions lower contamination from 
environmental high abundance proteins: in the presence of β-ME peaks were narrower but their height was not 
lower (Fig. 3). This demonstrates that, while the protein concentration of samples diminishes with the use of Tris 
and β-ME, samples do not lose intrinsic vesicle proteins, rather they are losing contaminants. This extravesicular 
protein removal is also confirmed by the analysis of the supernatants remaining after centrifugation used to pellet 
vesicle obtained after purification.
On the other hand, in addition to disulphide bridges, other ionic and non-ionic interactions may occur on 
the EVs surface. It is known that electrostatic interactions on hydrophilic surfaces are one of the main factors 
determining the adsorption of biomolecules on particle surfaces. Another cause of protein absorption could be 
the zeta potential of MVs surface, that can form ionic bonds carried by Phosphate2−, abundant in PBS46–48. For 
these reasons, it is likely that also other less abundant proteins, present in these two biological fluids, could bind 
to EVs rendering the analyses less reliable and complicating the process of biomarker discovery by MS. Based on 
our experiment results, gel electrophoresis clearly highlights the eventual presence of smeared protein patterns, 
characteristic of non-vesicular proteins. As a matter of fact, even if by a quantitative point of view, MS is the per-
fect choice, it is both time consuming and very expensive when compared to gel electrophoresis.
Blood is a commonly used biological sample acquiring a considerable interest due to its minimally invasive 
mode of collection and the information it can give thanks to its content in EVs. As far as blood is concerned, it 
has already been suggested that additional purification steps may be necessaryto eliminate contaminants from 
EVs41. Data show that, besides their biogenesis and function, EXOs are different from MVs especially for their 
propensity to bind non-vesicular high abundance proteins in each physiological milieu. In particular, it appears 
that a key feature of EXOs is their being players of surface interactions: it has been observed that EVs may repre-
sent a uniquely large interactive surface area, and the surface interactome may play a role in different physiolog-
ical and pathological processes. Data suggest that EXOs in particular have the ability to bind plasma and urine 
high abundance components, which may explain their recognized role in malignancies. Likely, high abundance 
proteins bind more to the EXOs, respect to MVs due to their relatively large surface to volume ratio. However, 
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the same EXOs sample split in aliquots bound more environmental proteins when treated with PBS/DTT than 
with Tris/β-ME. On the other hand, also MVs bind extravesicular proteins in urine (see uromodulin and albumin 
in Figs 7 and 8), although to a lower extent than EXOs. The overall level of extravesicular proteins bound to the 
EXOs was too high as compared to MVs, to be merely attributed to the higher surface to volume ratio of EXOs. 
We cannot rule out that fact that the characteristics of the milieu, of the environmental protein and also differen-
tial specific surface features can play a role in the binding of extra-vesicular protein to the EVs surface. Further 
studies are needed to study the physiological relevance of the EVs surface interactions.
Contamination from non-vesicular materials is a critical issue linked to centrifugation-based methods for 
EVs isolation, that can cause unwanted variability to the down-stream analyses. The ability to discern contam-
inant from bona fide EVs proteins would allow to define the EVs proteome composition fully exploiting the 
EVs biomarker potential. Isolation of both EXOs and MVs from blood with minimal contamination by plasma 
proteins is, therefore, of great importance in the search for biomarkers for example of solid and hematologic 
malignancies49,50. Haraszti et al.51 found a multi-protein marker phenotyping tool useful in different pathologies, 
cancer included. As a matter of fact, cancer cells release EXOs into blood to mediate tumour-related processes and 
metastases. As far as urinary tract malignancies are concerned, and considered that urinary EXOs contain most 
of the urinoma proteome, urine can become a non-invasive “liquid biopsy”52. with the potential to reduce tumor 
biopsies and to detect new useful biomarkers53–55. Precision medicine represents the starting point of a new epoch 
not only in the management of diseases in a less invasive way but also in the discovery and use of new biomarker 
for a better patient stratification56. For example, Clark et al.57 identified 2,179 proteins in EXOs purified from 
healthy human serum, thus since vesicles can be detected in blood and urines of patients with various diseases, 
the development of a platform that exploits their use as a diagnostic tool has been proposed by many Authors.
In conclusion, improving purity of both EXOs and MVs, especially those isolated from biological fluids, allows 
to increase the specificity and selectivity of the source of protein identification for biomarker search in various 
diseases, among which tumors. In view of this, new experimental designs will be possible, no longer altered by the 
noise of the biological environment displaying greater adherence to the physiopathology processes.
Methods
Materials. Sucrose, Tris (hydroxymethyl) aminomethane (Tris), β-mercaptoethanol (β-ME), Ethylene gly-
col-bis (2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), Dithiothreitol (DTT), Phosphate buffered saline 
(PBS), sodium phosphate, Tri-n-butylphosphine (TBP), Acrylamide, bis-acrylamide, Sodium dodecylsulphate 
(SDS), ammoniumpersulphate (APS), Tetra-methylethylene-diamine (TEMED), Glycine, Methanol, Bovine 
serum albumin (BSA), Tris-buffered saline (TBS) and Tween as well as all other analytical grade chemicals were 
from Sigma-Aldrich (St. Louis, Missouri, USA). FITC-Phalloidin was from Sigma-Aldrich (S. Luis, MO, USA.) 
IgG1 isotype controls (clone MOPC-21) and conjugated antibodies against CD41a (IgG1, clone HIP8), CD63 
(IgG1, clone H5C6) and CD81 (IgG1, clone JS-81) were from Becton Dickinson (CA, USA). Mega-Mix beads 
were from BioCytex (Stago Group). CoomassieG-250, SDS, broad range molecular mass calibration kit, Protean 
II xi cell system, Quantity one software analysis program vs. 4.5, VersaDoc 4000 and Molecular Imager GS-800 
calibrated densitometer were from BioRad (Hercules, CA, USA). Avanti™ J-25 centrifuge and Optima™ l–90 K 
were from Beckman (Brea, California, USA). Zetasizer Nano instrument (Malvern Instruments, Worcestershire, 
UK).
Complete protease inhibitor cocktail tablets were from Roche Diagnostics, (Basel, CH). Monoclonal mouse 
anti-human β-actin was kindly provided by MD Giulio Gabbiani, (University of Geneva, Switzerland). Polyclonal 
rabbit anti-human serum albumin (HSA) was purchased from Dako (Copenhagen F., Dk), Polyclonal sheep 
anti-human uromodulin was obtained from Abcam (Cambridge, UK), Polyclonal anti-human Apolopoprotein 
from NOVUS (Brussels, Belgium) and anti-rabbit and sheep peroxidase secondary antibodies were obtained 
from Immunological Sciences (Rome, Italy). Nitrocellulose Protean B membrane was from Whatman, (Boston, 
Ma, USA) while Super-Signal West Pico chemi-luminescent Substrate from Pierce, (Rockford, IL, USA).
Sample collection and storage. Serum (10 mL), plasma (10 mL) and the second morning urine (120 mL) 
from healthy donors (12 individuals, age 35–50 years, 6 males and 6 females) were collected after informed con-
sent. All samples were added with tablets of protease inhibitor immediately after collection, chilled on ice and 
centrifuged at 4 °C for 10 min respectively at 3,000 rpm or 1,000 × g to eliminate cell debris in accordance to 
Standard Protocols. The urines and sera were further centrifuged at 16,000 × g in a JA-20 rotor (Beckman Avanti 
J-25) for 30 min at 16 °C to remove microscopic particle sediments and mitochondrial fraction. Samples were 
pooled (three different pools, each consisting of two males and two females). An aliquot of 16,000 × g super-
natant, after Bradford protein assay, was dialyzed three times against 25 mM sodium phosphate pH 7.2 in 3500 
MWCO Spectra-Por cellulose membranes at 4 °C. Finally, supernatants were divided into several aliquots of 1 mL 
(serum and plasma) and 12 mL (urine) and stored at −80 °C until analysis. We obtained written approval of the 
protocol by the local Independent Ethics Committee (Comitato Etico Regione Liguria) on October 14, 2014 
(study number: 408REG2014).
Flow cytometry. Cytometer setting: before starting acquisition, LSRFortessa X-20 (Becton Dickinson), daily 
calibrated using CS&T beads (Becton Dickinson), was carefully washed with double-distilled water. According 
to Poncellet and Inglis58,59, FSC and SSC were set to log scale. Voltages were adjusted to the highest values that 
excluded the majority of background noise on the basis of DD water and pure ultracentrifuged (20,000 × g for 
10 minutes) PBS acquisition and that allowed the detection of all different dimensions (0.5, 0.24, 0.2, 0.16 um) of 
SSC MegaMix beads (BioCytex, Stago Group) and Rosette Calibration beads (Exometry, NL)60.
Serum and plasma extracellular vesicle pellets (both MVs and Exos) were stained with Phalloidin 
(high-affinity filamentous actin, F-actin), CellTrace FR (Thermofisher) and either CD41a or CD81 and CD63. 
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All fluorescent probes were ultracentrifuged (20.000 × g for 10 minutes) before using. Microvesicles were first 
gated on the basis of their physical dimensions then, to avoid cell debris, among CellTrace positive events, those 
negative for Phalloidin and positive for CD41a were chosen as possible platelet-derived MVs40. Exosomes, posi-
tive for CellTrace and negative for Phalloidin, were then tested for their CD81 and CD6361 expression. For what 
concern EXOs, given their small dimensions, to set the proper positivity cut off, we performed a single staining 
analysis62. All pellets were then resuspended in 300 μl of filtered PBS, acquired on LSRFortessa X-20 and analyzed 
using Kaluza software (Beckman Coulter).
Dynamic light scattering analysis. The size of EXOs and MVs was determined by dynamic light scatter-
ing (DLS) using a Zetasizernano ZS90 particle sizer at a 90° fixed angle (Malvern Instruments, Worcestershire, 
UK). The particle diameter was calculated using the Stokes–Einstein equation. For particle sizing in solution, 
EXOs or MVs aliquots were diluted in 10% PBS and analyzed at a constant 25 °C. The data were acquired and 
analyzed using Dispersion Technology Software (Malvern Instruments).
Isolation of serum and urinary extracellular vesicles. Extracellular vesicles were isolated from the 
supernatant of sera, plasma and urines. The micro-vesicles were isolated from the 16,000 × g supernatant by 
centrifugation at 22,000 × g in a JA-20 rotor (Beckman Avanti™ J-25) for 120 min at 16 °C. The 22,000 × g 
supernatant was ultracentrifuged at 100,000 × g in a Ti 90 rotor (Beckman Optima™ l–90 K) for 120 min at 16 °C 
to pellet the EXOs. An aliquot of each pellet was tested for protein content by Bradford protein assay. For each 
sample, the mean and standard deviation of the protein quantification is reported (MVs plasma 37 ± 2.6 μg/ml, 
serum 32 ± 2.2 μg/ml and urine 21 ± 1.5 μg/ml; EXOs 28 ± 2.0 μg/ml, serum 24 ± 1.7 μg/ml and urine 16 ± 1.1 μg/
ml). Until use, all samples were stored at −80 °C. Both urinary MVs and EXOs were routinely cytofluorimetrically 
assayed for the expression of specific markers, as previously reported9.
Density gradient centrifugation. To isolate EVs with higher purity, both 22,000 × g and 100,000 × g pel-
lets, prior to final washings with PBS, were subjected to further centrifugation in combination with sucrose cush-
ions. Pellets, resuspended in 1 mL of isolation solution (0.25 M sucrose in 50 mMTris density 1.018 g/ml) + 2.5% 
β-ME or 100 mM DTT (incubation at room temperature for 30 minutes), were loaded on 1 mL of 50 mM Tris or 
PBS in a 30% sucrose cushion (density 1.140 g/ml) and centrifuged at 22,000/100,000 × g for 120 min at 16 °C. 
This 50 mMTris buffer facilitates the solubilization of filaments and keeps uromodulin in solution. To remove 
remaining proteins and other contaminants, pellets were subsequently washed 3 times in 1 mL of PBS, always 
at 22,000/100,000 × g for 45 min at 4 °C. Bradford protein assay was also after density gradient centrifugation. 
Protein concentrations of MVs samples were: 30 ± 2.1, 25 ± 1.7 and 16 ± 1.1 µg/ml for plasma, serum and urine, 
respectively. Protein concentrations of EXOs samples were: 22 ± 1.5, 16 ± 1.2 and 11 ± 0.7 µg/ml for plasma, 
serum and urine, respectively. As described above, each pellet was further divided into aliquots and used for the 
different analyzes. Until use, all samples were stored at −80 °C.
SDS-PAGE, staining and western blot analysis. Serum and urinary extracellular vesicle pellets were 
dissolved and separated by gradient Sodium Dodecyl Sulphate - PolyAcrylamide Gel Electrophoresis (SDS-PAGE) 
according to Laemmli63 in a 8–16 T% polyacrylamide gels. After SDS-PAGE, proteins were visualized by a double 
staining procedure, based on methyl-trichloro-acetate64 followed by silver staining. Stained gels were digitized by 
using a GS-800 calibrated densitometer at 63.5 microns of resolution and analyzed with Quantity one software 
(Bio-Rad). In a second set of experiments, in which the loaded samples were aligned with β-actin, the proteins 
were trans-blotted to nitrocellulose protean membranes with a Novablot semidry system (GE Healthcare, Milan, 
Italy) using a continuous buffer system (2-amino 2-idroxymethyl 1,3-propanediol, 38 mM Tris, 39 mM glycine, 
0.035% SDS, and 20% methanol). The run was carried out for 2 h at 400 mA at 4 °C. Hybridisation was preceded 
by an overnight incubation at Tamb with a blocking solution of 3% (wt/vol) BSA in TBS 0.15% Tween. Incubation 
with primary antibodies (i.e. monoclonal mouse bona fide β-actin, polyclonal rabbit anti-human serum albumin 
HAS, polyclonal sheep anti-human uromodulin and polyclonal anti-human Apo-A1, Apo-E and Apo-C) diluted 
1:2000 (vol/vol), was performed overnight at room temperature in 3% (wt/vol) BSA in TBST. The membrane then 
was washed with TBST four times, 15 min each, before of the incubation with peroxidase-conjugated mouse, 
rabbit or sheep anti-human diluted 1:5000 (vol/vol) in 3% (wt/vol) BSA in TBS-T for 4 h at Tamb. The mem-
brane then was washed four times, 15 min each, before developing the immune-blot with the Super-Signal West 
Pico chemi-luminescent Substrate (Pierce, Rockford, IL). Chemi-luminescence was used to detect proteins after 
Western blot, signals being acquired with Versa Doc 4000 (Bio-Rad).
All the previously applied methods were carried out in compliance with the relevant guidelines and 
regulations.
Image analysis. Images were captured and analyzed by Quantity one software. Numbers and intensities of 
bands were exported for further analysis. To test the quality of each separation, for both EXO and MV, the num-
ber of bands visualized, their resolution and the presence, as contaminants, of albumin or uromodulin, Apo-A1, 
Apo-E or Apo-C in serum or urinary samples respectively, were taken into account. Results are representative of 
at least five experiments. All analyses were performed using package R software last version available at the time 
of experiments.
Statistical analysis. Kruskal-Wallis test was used to assess differences between all the protocols of EXOs or 
MVs purification. The results were expressed as mean and standard deviation. A value of P ≤ 0.05 was considered 
to be statistically significant. All statistical tests were performed using the latest version of software package R 
available at the time of the experiments.
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